Delivery Order SPE2DB24D3014-SPE2DB25FKUDY
- Not listed
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for Esbriet (pirfenidone) 801 mg tablets in a quantity of 90 units. This award, issued on July 21, 2025, with an ultimate completion date of August 11, 2025, represents a non-competitive delivery order under AmerisourceBergen's existing federal contract vehicle. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $6,851.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Esbriet (pirfenidone) 267 mg tablets in a quantity of 270 units. The contract was competitively awarded with no set-aside designation and is scheduled for completion by August 8, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The pharmaceutical will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg on July 30, 2025, with an ultimate completion date of August 20, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and...
- The Defense Logistics Agency (DLA) awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for the supply of Esbriet 267 mg tablets (270 count) on July 31, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Esbriet (pirfenidone) is a pharmaceutical treatment for idiopathic pulmonary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Esbriet (pirfenidone) 267 mg tablets in a quantity of 270 tablets. This is a firm fixed price delivery order with a ceiling value of $3,425.95 and an ultimate completion date of August 18, 2025. The contract is not set-aside and represents a competitive award to the vendor, with performance to take place at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg, a pharmaceutical product used in the treatment of pulmonary fibrosis. This firm fixed price, non-set-aside contract was awarded on August 4, 2025, with an ultimate completion date of August 25, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used to treat idiopathic pulmonary fibrosis. The contract, awarded on July 21, 2025, with an ultimate completion date of August 11, 2025, was competitively awarded without set-aside provisions. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,934.50 firm fixed-price delivery order is for the supply of 90-count tablets of the drug Esbriet (pirfenidone) 801 mg. The award has an ultimate completion date of December 3, 2024 and was issued on November 8, 2024. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for supply of Esbriet 267 mg tablets (270 count) under a firm fixed price contract valued at $6,851.90. The delivery order, issued on August 4, 2025, with an ultimate completion date of August 25, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office location. This delivery order is...
- SPE2DB24D3014Indefinite Delivery Contract
- SPE2DB24D3014-SPE2DB25FKUDYDelivery Order
The Defense Logistics Agency awarded a $10,277.85 delivery order to AmerisourceBergen Drug Corp for Esbriet (pirfenidone) 801 mg tablets, quantity 90, with an ultimate completion date of August 20, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle valued through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor and healthcare solutions provider for federal medical procurement, particularly supporting Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates proven capability in delivering specialized pharmaceuticals across multiple therapeutic domains through open competition. Esbriet, used primarily in the treatment of idiopathic pulmonary fibrosis, underscores the company's role in supplying specialty medications to support military medical readiness and veteran healthcare requirements through the DLA Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 7/30/25 |